Retinoid X receptor alpha:Peroxisome proliferator-activated receptor gamma heterodimer (RXRα:PPARγ)

The Retinoid X receptor alpha:Peroxisome proliferator-activated receptor gamma (RXRα:PPARγ) heterodimer is a ligand-activated transcription factor complex that serves as a master regulator of adipogenesis and systemic glucose homeostasis (NIH, 2024). It functions as a permissive heterodimer, meaning it can be activated by ligands for either PPARγ, such as thiazolidinediones, or RXRα, such as rexinoids, or both simultaneously for a synergistic effect (Frontiers in Pharmacology, 2024). Upon activation, the complex binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes involved in lipid storage, insulin signaling, and energy metabolism (PubMed, 2010). In metabolic diseases like type 2 diabetes and obesity, the activity of this heterodimer is often impaired, leading to insulin resistance and dyslipidemia (NIH, 2023). Pharmacological targeting of the RXRα:PPARγ complex has been a cornerstone of diabetes therapy, although its use is sometimes limited by side effects like weight gain and fluid retention (ResearchGate, 2024). Beyond metabolism, the heterodimer also plays roles in inflammation and cell differentiation, making it a subject of interest in oncology and immunology research (UniProt, 2024).

Other names

RXRA:PPARGPPARG:RXRARXR-PPAR gamma complexNR2B1:NR1C3 heterodimer

The RXRα:PPARγ heterodimer functions as a permissive complex that activates transcription upon binding of agonists to either the PPARγ or RXRα subunit. Ligand binding induces a conformational change that promotes the release of corepressors (e.g., SMRT, NCoR) and the recruitment of coactivators (e.g., CBP/p300, SRC-1), leading to the binding of the complex to peroxisome proliferator response elements (PPREs) on DNA to regulate gene expression.